"Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy

KevinD Mullen, Karen Szauter, Kristine Kaminsky-Russ

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

Body fluids from patients with hepatic encephalopathy and from controls with no renal or hepatic disease were assayed for benzodiazepine immunoreactivity and benzodiazepine-receptor-binding activity. The subjects had taken no synthetic benzodiazepines for at least 3 months. Benzodiazepine receptor binding in cerebrospinal fluid was significantly higher in hepatic encephalopathy patients than in controls (210 [SE 50·2] vs 40·7 [7·3] oxazepam equivalents [ng/ml]). The severity of hepatic encephalopathy was directly and significantly correlated with the level of benzodiazepine activity by radioreceptor assay or radioimmunoassay in urine and in plasma. Benzodiazepine activity equivalent to levels of more than 900 ng/ml was found in patients with advanced encephalopathy. Although the chemical identity and source of this substance (or substances) are still unknown, its properties and the estimated levels of activity suggest it may have a role in the pathogenesis of the neural inhibition seen in hepatic encephalopathy.

Original languageEnglish (US)
Pages (from-to)81-83
Number of pages3
JournalThe Lancet
Volume336
Issue number8707
DOIs
StatePublished - Jul 14 1990
Externally publishedYes

Fingerprint

Hepatic Encephalopathy
Body Fluids
Benzodiazepines
GABA-A Receptors
Neural Inhibition
Oxazepam
Radioligand Assay
Brain Diseases
Radioimmunoassay
Cerebrospinal Fluid
Urine
Kidney
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

"Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. / Mullen, KevinD; Szauter, Karen; Kaminsky-Russ, Kristine.

In: The Lancet, Vol. 336, No. 8707, 14.07.1990, p. 81-83.

Research output: Contribution to journalArticle

Mullen, KevinD ; Szauter, Karen ; Kaminsky-Russ, Kristine. / "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. In: The Lancet. 1990 ; Vol. 336, No. 8707. pp. 81-83.
@article{fcd125e834294222bc123b848fa4d8f9,
title = "{"}Endogenous{"} benzodiazepine activity in body fluids of patients with hepatic encephalopathy",
abstract = "Body fluids from patients with hepatic encephalopathy and from controls with no renal or hepatic disease were assayed for benzodiazepine immunoreactivity and benzodiazepine-receptor-binding activity. The subjects had taken no synthetic benzodiazepines for at least 3 months. Benzodiazepine receptor binding in cerebrospinal fluid was significantly higher in hepatic encephalopathy patients than in controls (210 [SE 50·2] vs 40·7 [7·3] oxazepam equivalents [ng/ml]). The severity of hepatic encephalopathy was directly and significantly correlated with the level of benzodiazepine activity by radioreceptor assay or radioimmunoassay in urine and in plasma. Benzodiazepine activity equivalent to levels of more than 900 ng/ml was found in patients with advanced encephalopathy. Although the chemical identity and source of this substance (or substances) are still unknown, its properties and the estimated levels of activity suggest it may have a role in the pathogenesis of the neural inhibition seen in hepatic encephalopathy.",
author = "KevinD Mullen and Karen Szauter and Kristine Kaminsky-Russ",
year = "1990",
month = "7",
day = "14",
doi = "10.1016/0140-6736(90)91594-Z",
language = "English (US)",
volume = "336",
pages = "81--83",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8707",

}

TY - JOUR

T1 - "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy

AU - Mullen, KevinD

AU - Szauter, Karen

AU - Kaminsky-Russ, Kristine

PY - 1990/7/14

Y1 - 1990/7/14

N2 - Body fluids from patients with hepatic encephalopathy and from controls with no renal or hepatic disease were assayed for benzodiazepine immunoreactivity and benzodiazepine-receptor-binding activity. The subjects had taken no synthetic benzodiazepines for at least 3 months. Benzodiazepine receptor binding in cerebrospinal fluid was significantly higher in hepatic encephalopathy patients than in controls (210 [SE 50·2] vs 40·7 [7·3] oxazepam equivalents [ng/ml]). The severity of hepatic encephalopathy was directly and significantly correlated with the level of benzodiazepine activity by radioreceptor assay or radioimmunoassay in urine and in plasma. Benzodiazepine activity equivalent to levels of more than 900 ng/ml was found in patients with advanced encephalopathy. Although the chemical identity and source of this substance (or substances) are still unknown, its properties and the estimated levels of activity suggest it may have a role in the pathogenesis of the neural inhibition seen in hepatic encephalopathy.

AB - Body fluids from patients with hepatic encephalopathy and from controls with no renal or hepatic disease were assayed for benzodiazepine immunoreactivity and benzodiazepine-receptor-binding activity. The subjects had taken no synthetic benzodiazepines for at least 3 months. Benzodiazepine receptor binding in cerebrospinal fluid was significantly higher in hepatic encephalopathy patients than in controls (210 [SE 50·2] vs 40·7 [7·3] oxazepam equivalents [ng/ml]). The severity of hepatic encephalopathy was directly and significantly correlated with the level of benzodiazepine activity by radioreceptor assay or radioimmunoassay in urine and in plasma. Benzodiazepine activity equivalent to levels of more than 900 ng/ml was found in patients with advanced encephalopathy. Although the chemical identity and source of this substance (or substances) are still unknown, its properties and the estimated levels of activity suggest it may have a role in the pathogenesis of the neural inhibition seen in hepatic encephalopathy.

UR - http://www.scopus.com/inward/record.url?scp=0025292201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025292201&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(90)91594-Z

DO - 10.1016/0140-6736(90)91594-Z

M3 - Article

C2 - 1975325

AN - SCOPUS:0025292201

VL - 336

SP - 81

EP - 83

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8707

ER -